Literature DB >> 21478752

Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010.

Valérie Jooste1, Laurent Remontet, Marc Colonna, Aurélien Belot, Guy Launoy, Florence Binder, Jean Faivre, Anne-Marie Bouvier.   

Abstract

The aim of this study was to present estimates of national trends in the incidence of the most frequent digestive cancers over the period 1980-2005 and to provide projections up to 2010. World age-standardised estimates of national incidence were modelled using data from the French cancer registries and the incidence/mortality ratios observed in the area covered by the contributing registries, using an age-period-cohort model. The incidence of oesophageal cancers in men strongly decreased over time from 15.3 in 1980 to 7.9 per 100 000 in 2005, whereas the incidence in women slowly increased. A steadily decreasing trend in gastric cancer was found in both sexes. After a steady increase until 1995, the incidence of colorectal cancer stabilised in both sexes, with a slight decrease in men. In 2010, the projected incidence was 36.5 per 100 000 in men and 24.4 in women. The incidence of liver cancer showed the highest increase over time. In men, this increase was steeper until 1995 than later. The projected incidence in 2010 was 10.9 per 100 000 in men and 2.4 in women. The incidence of pancreatic cancer increased slowly between 1980 and 1990 and increased steeply after 1990, reaching an estimated 7.6 per 100 000 in men and 4.7 in women in 2005. This study on trends in the incidence of digestive cancers in France showed large changes between 1980 and 2010. The increase in the incidence of primary liver cancer and pancreatic cancer was striking. Colorectal cancer incidence is stabilising.

Entities:  

Mesh:

Year:  2011        PMID: 21478752     DOI: 10.1097/CEJ.0b013e3283465426

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  9 in total

1.  Primary Surgery for Malignant Large Bowel Obstruction: Postoperative Nasogastric Tube Reinsertion is Not Mandatory.

Authors:  A Venara; J Barbieux; P A Colas; A Le Fouler; E Lermite; A Hamy
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 2.  Perspectives of gold nanoparticles and their applications in pancreatic cancer (Review).

Authors:  Anamaria Magdalena Tomşa; Andreea Liana Răchişan; Andreea Alexandra Aldea; Lorena Ciumărnean
Journal:  Exp Ther Med       Date:  2021-01-25       Impact factor: 2.447

Review 3.  Effects of tobacco constituents and psychological stress on the beta-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: implications for intervention.

Authors:  Hildegard M Schuller
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

4.  Incidence of colorectal cancer in Poland in 1999-2008.

Authors:  Alicja Klimczak; Bogumiła Kempińska-Mirosławska; Michał Mik; Lukasz Dziki; Adam Dziki
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

Review 5.  Interleukin-10-819 promoter polymorphism in association with gastric cancer risk.

Authors:  Huiping Xue; Bing Lin; Jianfu An; Yuyuan Zhu; Gang Huang
Journal:  BMC Cancer       Date:  2012-03-21       Impact factor: 4.430

Review 6.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

Authors:  A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki
Journal:  J Gastrointest Cancer       Date:  2015-09

7.  A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.

Authors:  Emilie Lereclus; Mira Tout; Alban Girault; Nadine Baroukh; Morgane Caulet; Christophe Borg; Olivier Bouché; David Ternant; Gilles Paintaud; Thierry Lecomte; William Raoul
Journal:  BMC Cancer       Date:  2017-03-27       Impact factor: 4.430

8.  Adapted Fencing for Patients With Invasive Breast Cancer: The RIPOSTE Pilot Randomized Controlled Trial.

Authors:  Abdou Y Omorou; Didier Peiffert; Christine Rotonda; Aurélie Van Hoye; Edem Allado; Oriane Hily; Margaux Temperelli; Bruno Chenuel; Dominique Hornus-Dragne; Mathias Poussel
Journal:  Front Sports Act Living       Date:  2022-03-29

9.  A meta-analysis of interleukin-10 -592 promoter polymorphism associated with gastric cancer risk.

Authors:  Huiping Xue; Ying-Chao Wang; Bing Lin; Jianfu An; Lu Chen; Jinxian Chen; Jing-Yuan Fang
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.